L-Arginine

Clinical Summary

L-Arginine is a conditionally essential amino acid and the substrate for nitric oxide synthase (NOS). Oral supplementation modestly raises plasma arginine, but ~40% first-pass arginase extraction in gut and liver means plasma arginine rises are smaller and shorter than equimolar L-citrulline (which bypasses arginase). This pharmacokinetic disadvantage is the central fact of the monograph: for most cardiovascular and exercise goals, L-citrulline is the pharmacologically superior choice.

Arginine's genuine evidence base is narrower than its reputation. Best-supported indications are (1) mild-to-moderate erectile dysfunction in combination with Pycnogenol (multiple positive RCTs, EAU weak recommendation), (2) preeclampsia prevention in high-risk pregnancies (Makama 2025 meta-analysis, RR 0.52), (3) sickle-cell disease vaso-occlusive pain (Morris 2025 Phase 2 positive), and (4) adjunctive nutrition in pressure ulcers / chronic wounds (as arginine+glutamine+HMB formulas).

The supplement's reputation as a "NO booster" for healthy adults, GH releaser, or pre-workout pump agent is largely unsupported — decades of RCTs show null or weak effects outside the above niches. More concerning: the VINTAGE-MI trial (JAMA 2006) halted early when 6/70 post-MI patients died on arginine versus 0/70 on placebo. Oral arginine is contraindicated after acute myocardial infarction, and caution applies to older adults with established atherosclerosis or endothelial dysfunction. If you are a healthy adult looking to support NO signaling, use citrulline. If you have mild ED and want to try a supplement, consider the arginine+Pycnogenol stack. If you have anything else cardiovascular in your history, discuss with your cardiologist first.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = causal relationship strength. BH = Bradford Hill criteria met (/9). Safety = FAERS / trial signals for THIS specific indication.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type.

Type codes: DC=Direct causation | PC=Probable causation | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (manageable AEs) | WARN FAERS / trial safety signal | AVOID Contraindicated for this indication

Star rating legend: 5/5 = multiple large RCTs + meta-analyses | 4/5 = several human RCTs | 3/5 = some human pilot | 2/5 = animal or very limited human | 1/5 = none / debunked / harmful

Prescribing

Dosing Table

Formulation Table

Pharmacokinetic note: oral arginine peaks plasma at 1-2 h, half-life ~1-2 h. Sustained elevation requires divided doses. Equimolar oral L-citrulline produces a higher and longer-lasting plasma arginine rise than L-arginine itself.

Condition-Specific Protocols

Erectile Dysfunction (mild-to-moderate) Protocol

Evidence: 4/5 | Key PMIDs: 30770070 (Rhim meta-analysis), 37908749 (Tian combo MA), 12851125 (Stanislavov original), 39279185 (Barbonetti network MA)

Phase 1: Initiation (Weeks 1-2)

• Dose: 2.5 g L-arginine BID (5 g/day total) with 40-60 mg Pycnogenol once daily.
• Monitor: subjective erection quality (IIEF-5 self-scoring at baseline + week 4 + week 8); BP weekly if hypertensive.
• Goal: confirm GI tolerance; identify PDE5i-stacking opportunities.

Phase 2: Therapeutic (Weeks 3-12)

• Dose: maintain 5 g/day arginine + 80-120 mg Pycnogenol.
• Monitor: IIEF-5 at 4-week intervals; cold-sore breakout if HSV-prone.
• Expected outcome: IIEF-5 improvement typically visible by week 4-8. Response rate ~60-70% in clinical literature (Stanislavov 80-90% in original trial — likely overstated).

Phase 3: Maintenance (Week 12+)

• Continue effective dose. If no improvement after 12 weeks, discontinue — unresponsive phenotype (may reflect venous leak or other non-NO etiology).
• Consider adding / switching to PDE5i if insufficient (well-studied additive effect per Xu 2021, PMID 33587304).

Drug Interaction Timing: If adding sildenafil 25-50 mg PRN, take ≥4 h after morning arginine dose to avoid compound hypotension. Monitor BP if using any antihypertensive. Expected Outcomes: IIEF-5 gain of 3-5 points typical in responders; no change in testosterone. Stop/Reassess Criteria: No subjective improvement after 12 weeks; any syncope or symptomatic hypotension; new cardiac symptoms (contraindication check).

Preeclampsia Prevention (OB-directed, high-risk pregnancies) Protocol

Evidence: 4/5 | Key PMIDs: 39800868 (Makama 2025 BJOG, n=2028), 22957482 (Zhu 2013), 37258415, 37789125 (CHERRY, citrulline), 39638148

This protocol is for OB/MFM-directed use only. DO NOT self-initiate arginine in pregnancy. Listed here because the evidence base is strong enough to reference during clinical discussions.

Phase 1: Initiation (early 2nd trimester, high-risk identification)

• Typical trial doses: 3 g/day to 15 g/day (often as arginine + citrulline combination or as arginine-enriched medical food such as Medox or Vitergin used in European trials).
• Monitor: BP weekly; urine protein; fetal growth surveillance per high-risk OB protocol.

Phase 2: Therapeutic (through 3rd trimester)

• Dose: continue trial-dose arginine; adjust per OB guidance.
• Expected biomarker changes: SBP -5.6 mmHg average; reduced sFlt-1/PlGF ratio (in L-citrulline CHERRY trial); reduced FGR rates (RR 0.46).

Phase 3: Postpartum

• Discontinue after delivery unless continuing for lactation support (no data).

Stop/Reassess Criteria: Any sign of maternal hypotension; fetal monitoring concerns; uncertain benefit weighed against any new GI or hemodynamic concern.

Sickle-Cell Disease VOC (hematology-directed) Protocol

Evidence: 4/5 | Key PMIDs: 40270092 (Morris Phase 2 2025), 35426778 (Onalo 2022 pediatric), 41534622 (Foncha 2026 MA)

Inpatient VOC pain management (acute): 100 mg/kg IV loading then IV maintenance per hematology protocol. Outpatient maintenance (under study): oral L-arginine under hematologist supervision; dose and duration per STArT Phase 3 trial protocol (PMID 37587492).

Expected Outcomes: Reduction in opioid requirement during VOC; improved vascular hemodynamics (Onalo 2022). Stop/Reassess Criteria: No data supporting use outside active VOC or specific research protocols.

Safety

Interactions Table

Contraindications

• Post-acute myocardial infarction — VINTAGE-MI excess mortality signal (6/70 vs 0/70, trial halted early). Oral arginine is contraindicated after STEMI, at minimum for the 6-month post-event window and likely longer in older adults with endothelial dysfunction.
• Sepsis / critical illness (theoretical) — NO overproduction may worsen hemodynamic instability; enteral nutrition protocols sometimes still use arg+glu+HMB, but this is different from solo supplementation.
• Active herpes simplex (cold sore, genital) — high-dose arginine may promote viral replication; folk wisdom + in vitro mechanism; defer until lesion resolves.
• Known ASS1-deficient malignancy — theoretical: ADI-PEG20 (pegargiminase, JAMA Oncol 2024 PMID 38358753) is therapeutic in mesothelioma and some HCC by depleting arginine; supplementing in these tumors is the opposite of therapy. Low-probability but real concern for older patients with unknown tumor status. (Note: this concern is hypothetical for supplement users; do not use it to fearmonger against arginine in general.)
• Severe renal impairment (GFR <30) — paucity of safety data; aging kidney literature (Frontiers Pharmacol 2020) raises concern over chronic high-dose use; discuss with nephrologist.
• Pediatrics (except under specialist care for SCD or urea cycle disorders) — no routine indication.

Adverse Effects (ranked by frequency in oral supplement use)

1. Diarrhea / GI distress / nausea / bloating — dose-dependent, usually >6 g single dose or >9 g/day total; most common reason for discontinuation.
2. Headache — likely vasodilation-related; mild and transient.
3. Flushing / lightheadedness — vasodilation; more pronounced in BP-sensitive individuals.
4. Cold-sore / HSV reactivation — community-reported; plausible mechanism (lysine/arginine ratio).
5. Hypotension — especially when stacked with PDE5i or antihypertensives.
6. Fatigue / asthenia — reported in FAERS suspect-only subset (~62 reports); unclear causality.

FAERS Signal Table (from BioMCP, OpenFDA 2026-04-17)

Reading FAERS data: Supplement FAERS data is noisy — most "serious" reports for arginine are from IV parenteral nutrition formulations (CLINIMIX, TROPHAMINE, AMINOSYN, KABIVEN) or perindopril-arginine (ACE inhibitor salt), NOT oral supplementation. Reports of cerebral hemorrhage, AKI, sepsis, hypotension reflect the ICU parenteral-nutrition population. Apply the FAERS-supplement-noise filter. The oral-attributable suspect signal is ~370 reactions total, dominated by GI + fatigue + headache — mechanistically consistent with vasodilation. The dyspnea cluster in the hypertension-indication subset is the most concerning quasi-signal and aligns with the VINTAGE-MI pathophysiologic lesson.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Post-Myocardial Infarction

Synergies & Stacking

Antagonism / caution:

• High-dose Lysine (>3 g/d) may compete with arginine for absorption; matters for HSV-prone users who WANT to suppress arginine's viral-substrate effect.
• Avoid stacking with nitrates (nitroglycerin, isosorbide) — severe hypotension.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No clinically significant MTHFR / APOE / COMT effect documented for L-arginine specifically.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-negative across ~1000-2000 aggregated community mentions (Reddit, Longecity, bodybuilding forums, WebMD reviews). The near-universal biohacker consensus in 2024-2026 is "citrulline > arginine" for cardiovascular and exercise goals. Arginine retains a defensible niche in the arginine + Pycnogenol ED stack and as a cheap legacy option. Older bodybuilding forums universally call NO-boosters "the biggest scam in supplement history."

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: Some network-marketing brands push high-dose arginine (Synergy ProArgi-9, Juice Plus-adjacent) with "Nobel Prize heart health" messaging referencing Ignarro 1998 NO Nobel. Flag these hard; such products are typically 2-5x the price of equivalent USP arginine.
• Influencer concentration: Hype peaked 2005-2015 (BSN NO-Xplode era). Current biohacker influencers (Attia, Rogan) rarely recommend arginine; Pycnogenol+arginine ED stack is the one exception still promoted by sexual-health voices.
• Proprietary blends: Pre-workouts routinely hide sub-therapeutic arginine doses in proprietary blends (44% of ingredients hidden per multi-ingredient review). Avoid; buy single-ingredient USP arginine if trialing.
• Commercial bias: Most positive reviews on men's-health sites are affiliate-driven. Peer forums (Reddit, Longecity) are more honest.
• Astroturfing signals: AAKG and "NO booster" categories show unusually high review volume on generic-looking marketplace listings; suspect paid reviews.

Folk vs Clinical Reality Check

Community consensus is more skeptical than the clinical literature for solo arginine (CV, pump, GH) and more enthusiastic for the arginine+Pycnogenol ED combo. Biohackers correctly intuit that citrulline is pharmacologically superior for sustained NO — this aligns with the first-pass arginase / bioavailability literature. Divergences are mostly explained by placebo-washout at community dosing (3-6 g) versus therapeutic clinical dosing (≥9 g for BP), and by responder-heterogeneity from unmeasured ADMA/ARG1 status. The HSV-trigger folk wisdom has a plausible in-vitro mechanism but weak direct RCT evidence — a classic "probably real in HSV-prone individuals, invisible in mixed populations" signal.

Deep Dive: Mechanisms & Research

Mechanisms with clinical translation

• NO substrate via eNOS: L-arginine → citrulline + NO. Underlies vasodilation, BP reduction, and endothelial effects. Clinically translated for BP (meta-analyses) and ED. Caveat: plasma arginine rarely limits NO production in healthy endothelium (Km of eNOS for arginine ~3 μM; plasma arginine ~80-100 μM). The "arginine paradox" — why supplementation helps despite normal substrate availability — is explained by eNOS uncoupling, ADMA inhibition, and intracellular compartmentalization.
• eNOS uncoupling in disease: Under oxidative stress or BH4 deficiency, eNOS produces superoxide instead of NO. In this state, arginine supplementation may actually increase superoxide output (VINTAGE-MI mechanism hypothesis).
• Arginase compartmentalization: Red-cell ARG1 is the dominant human sink for arginine (not endothelial arginase as in rodent models). PMID 40729962 Heuser 2025.
• ADMA axis: Asymmetric dimethylarginine is a competitive endogenous inhibitor of eNOS. High-ADMA states (CKD, OSA, CVD) blunt arginine response. PMIDs 40797410, 40429627.
• Urea cycle / ammonia clearance: Clinically essential in CTLN1 (citrullinemia); therapeutic rescue dose.
• Immune / wound healing: Substrate for ornithine → proline → collagen; also iNOS → NO for macrophage function.
• GH secretion: IV arginine 0.5 g/kg reliably stimulates GH (standard pituitary provocation test). Oral doses in supplement range produce minimal, blunted, age-attenuated response.

Mechanisms with weak/no clinical translation

• Mitochondrial biogenesis via NO-cGMP-PGC1α (PMID 39707340, preclinical in diabetic cardiomyopathy) — promising but not yet clinically actionable.
• LAT1-NRF2 axis in placenta (PMID 41087351) — mechanistic explanation for preeclampsia effect, not independently actionable.
• iNOS reclassification (PMID 40389042) — may matter for inflammatory contexts; not yet actionable.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

330 total registered trials for "arginine" on ClinicalTrials.gov; many are vasopressin/oxytocin/pegargiminase trials captured by keyword match rather than oral L-arginine supplementation studies. Above are representative oral-arginine supplementation trials.

Regulatory Status

• FDA: L-arginine HCl injection approved as R-Gene 10 (NDA016931, Pfizer/Pharmacia) — IV provocative test for pituitary GH reserve. Oral L-arginine is marketed as dietary supplement under DSHEA — no FDA drug approval required. No FDA black-box warning despite VINTAGE-MI signal.
• EMA: LysaKare (L-arginine + L-lysine HCl, EMEA/H/C/004541) authorized for renal protection during Lutathera PRRT (radioligand therapy). Multiple amino-acid parenteral nutrition formulations authorized.
• WADA 2026: NOT prohibited. L-arginine is a natural amino acid; only GH-releasing peptides (GHRP, CJC-1295) are prohibited under S2. Use informed-sport-certified product to avoid contamination.
• Regulatory context: Never developed as a CV drug after VINTAGE-MI derailed the post-MI indication. Commercial viability and lack of patent incentive keep it in supplement channels.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature: "It's just an amino acid, can't be harmful." VINTAGE-MI refutes this directly for post-MI context.
• Appeal to authority: "Nobel Prize for NO" (Ignarro 1998) is misapplied — Nobel was for eNOS discovery, not for arginine supplementation efficacy. MLM marketing exploits this conflation.
• Hasty generalization: Extrapolating IV arginine GH-provocation response to oral supplementation for GH boosting. Dose, route, and context are radically different.
• Cherry-picking: ED meta-analyses include Pycnogenol-combo trials mixed with solo trials; pulling apart shows solo arginine effect is weaker than combo.
• Argument from popularity (bodybuilding): NO-booster category was a multi-billion-dollar segment based on pump-feel rather than ergogenic data. Community has since corrected this.
• Sunk cost / legacy: Arginine retains RCT volume advantage over citrulline simply because it was studied first; does not mean it is the better choice.

Evidence Gaps

• No head-to-head RCT comparing arginine vs citrulline at equimolar doses for BP, ED, or preeclampsia.
• No genotype-stratified RCT (NOS3, ASS1, ARG1) identifying who responds to arginine.
• No large Phase 3 outcomes trial for preeclampsia prevention (Makama 2025 calls for this explicitly).
• No long-term (>12 months) safety data in chronic high-dose (>9 g/d) use beyond post-MI signal.
• Sparse 2024-2026 data on oral arginine for male fertility / sperm quality — citrulline has gotten the attention.
• No clear understanding of tachyphylaxis (community "stops working after 2-3 weeks" anecdote).
• No modern Phase 3 trial explicitly replicating or refuting VINTAGE-MI with contemporary post-MI care.

Bias Flags (Mode 4: First Principles)

• Supplement industry overstates: "NO booster" marketing, proprietary blends, AAKG positioning — inflates perceived efficacy.
• Legacy RCT advantage: Arginine's first-mover position in NO-substrate research creates publication volume that overstates its superiority over citrulline.
• Responder self-selection: Positive anecdotes come from the ~30-60% who respond; the majority null response is under-reported.
• VINTAGE-MI narrative softening: Subsequent reviews sometimes downplay the trial ("small N," "old patients only") — but the mechanistic hypothesis (eNOS uncoupling in aged/damaged endothelium producing superoxide) has only strengthened since 2006.
• Pharma disinterest: Arginine is not patentable; no sponsor with incentive to replicate VINTAGE-MI with modern care or to push for regulatory upgrade of indication.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "NO booster" and "pump" categories (2005-2015 peak); proprietary pre-workout blends hiding sub-therapeutic doses; AAKG as "superior form" despite refutation (Campbell 2006); MLM "Nobel Prize heart health" messaging.
• Influencer economics: Peer biohacker community (Attia, Rogan, Huberman) largely doesn't push arginine in 2024-2026 — a mild countersignal to legacy marketing. Men's-health affiliate sites still promote arginine+Pycnogenol combo products (Prelox, Lady Prelox).
• Counter-narrative manipulation: Pharma has no meaningful incentive to fearmonger arginine (it is not a patented competitor to any product). VINTAGE-MI signal originated from academic investigators, not a competitor — this lends it credibility.
• Cui bono summary:
  • Wins if you take it: supplement industry (low-margin staple), Pycnogenol combo product brands (Horphag, Prelox), MLM distributors, research groups sustaining grant pipeline on arginine trials.
  • Wins if you don't: citrulline manufacturers (gaining share), PDE5i pharma (ED market retention), cautious cardiologists (fewer patient adventures post-MI).
• Red team highlight (most concerning angle): Stranger test — if a random person handed you a bottle and said "here's a Nobel Prize heart-health supplement," you should immediately ask (a) do you have recent MI or atherosclerosis? (avoid) (b) do you have HSV? (caution) (c) have you considered citrulline at half the GI side-effects? (probably yes). The gap between marketing positioning and honest use-case is wide.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 5/10 — real evidence for narrow indications (ED+Pycnogenol, preeclampsia in high-risk pregnancy, SCD VOC, wound healing in clinical nutrition contexts); null-to-weak for exercise/pump/GH; contraindicated post-MI. Compound-intrinsic score; NOT a comment on fit to any stack.
• Opportunity cost: Low financial ($5-15/month for USP arginine); moderate attention (GI limits compliance); displaces citrulline which is usually the better choice for the same goals.
• Verdict: CONDITIONAL
• Conditions:
  • USE if: mild-to-moderate ED and wanting to trial a supplement stack before PDE5i (arginine + Pycnogenol 5 g / 80-120 mg).
  • USE if: OB/MFM has recommended arginine for preeclampsia prevention in a high-risk pregnancy.
  • USE if: sickle-cell disease VOC, under hematologist direction.
  • USE if: chronic wound and a clinical nutritionist recommends arg+glu+HMB.
  • CONSIDER if: mild hypertension and seeking a non-pharmacologic adjunct (but prefer citrulline for pharmacokinetic reasons).
  • AVOID if: any history of MI, acute coronary syndrome, or active atherosclerosis — until cardiology clears.
  • AVOID if: active HSV outbreak.
  • SKIP in favor of citrulline if: general NO support, exercise, pump, or cardiovascular maintenance is the goal.
  • SKIP if: hoping for oral GH boost — it doesn't work at these doses.

Bottom Line

L-arginine is a narrow-utility supplement with a few well-supported niches (ED+Pycnogenol, high-risk preeclampsia, SCD, clinical wound nutrition) and a large legacy-marketing halo that exceeds its evidence base. For most cardiovascular and exercise goals, L-citrulline is pharmacologically superior — better absorbed, longer-acting, gentler on the GI tract, cheaper effective dose. The VINTAGE-MI safety signal is real and specific: do not take arginine after an acute MI. For a healthy adult with no specific indication, arginine is not a compelling supplement choice; for specific narrow indications where evidence exists, it can be useful. Choose deliberately based on indication, not on NO-substrate marketing generalities.

Practical Notes

Brands & Product Selection

• USP-grade free-base L-arginine (bulk powder or capsules) from reputable brands (NOW Foods, Bulk Supplements, Pure Encapsulations, Doctor's Best) at $0.05-0.15/g.
• For ED stack: consider Prelox or Lady Prelox (Horphag-formulated arginine + Pycnogenol) — standardized, matches clinical trial formulation. More expensive ($40-60/mo) but consistent dosing.
• For wound healing: Juven, Arginaid Extra, or Abound (standardized arg+glutamine+HMB medical foods) — typically insurance-covered with prescription.
• Avoid: Proprietary blends (pre-workouts with undisclosed arginine content); AAKG-only products (no ergogenic advantage over free base); MLM brands with "Nobel Prize" marketing at 3-5x USP price.
• CoA: Request Certificate of Analysis for heavy metals and microbial contamination if buying bulk powder. Informed-Sport certification for competitive athletes.

Storage & Handling

• Store in cool, dry place (<25°C). Powder is hygroscopic — keep desiccant in container after opening.
• Capsules stable 2-3 years at room temperature; powder ~1-2 years once opened.
• Liquid formulations (occasional) have shorter shelf-life and are typically inferior to powder/capsule.
• Rancidity is not a concern (amino acid, not a fat/oil).

Palatability & Compliance

• Free-base arginine has a bitter, slightly fishy taste in water — mix with citrus juice or take capsules.
• Arginine HCl is more soluble but acidic; buffer with a small amount of bicarbonate or take with food.
• Divided dosing (2-3x/day with meals) is essential for GI tolerance at therapeutic ≥5 g/day.
• Biggest compliance killer: GI distress at >6 g single dose. Most people who quit do so from diarrhea, not from lack of effect.

Exercise & Circadian Timing

• Pre-workout use (bodybuilding paradigm): weak evidence; citrulline malate is the better choice for pump/performance.
• Preschedule before sex (ED indication): 45-60 min before intimacy if using for acute erectile support; chronic daily dosing is the evidence-based pattern (not PRN).
• AM vs PM: no strong circadian evidence; divided dosing AM/PM with meals is standard.
• Avoid PM dose if stimulation or insomnia occurs (minority experience; some report opposite).

Reference Ranges (Expected Biomarker Changes)

Cost

• USP arginine powder (bulk): ~$0.05-0.10 / g. At 5 g/day, ~$8-15/month.
• Capsule form (500-1000 mg): ~$0.10-0.20 / g. At 5 g/day, ~$15-30/month.
• Arginine + Pycnogenol combos (Prelox): ~$40-60/month.
• Medical food (Juven/Abound): ~$80-150/month (prescription, often insurance-covered).
• L-Citrulline comparison: ~$0.08-0.20 / g; 3-6 g/day produces superior plasma arginine response; often better value for NO-substrate goals.

What We Don't Know

• Whether VINTAGE-MI's excess mortality signal extends beyond post-STEMI elderly to broader atherosclerosis populations.
• Whether genotype stratification (NOS3, ARG1, ASS1, DDAH variants) can identify a "super-responder" subset.
• Whether the preeclampsia effect is specifically an arginine effect or a general NO-substrate / citrulline effect.
• Whether chronic high-dose use (>5 years) causes subclinical endothelial senescence (aging-kidney / aging-endothelial preclinical signals).
• Whether oral arginine has any meaningful GH effect in non-elderly, non-obese adults at sub-pharmacologic doses.
• Whether the "tachyphylaxis" community anecdote reflects a real biological phenomenon or placebo-washout.
• Whether topical arginine formulations (hair, skin) have any skin-level effect beyond vehicle.
• Whether arginine is unsafe in occult ASS1-deficient malignancy (theoretical concern never tested).
• Whether lysine co-supplementation materially changes HSV outbreak frequency in HSV-positive supplement users.
• Optimal dose and timing for arginine+Pycnogenol ED stack — original Stanislavov dose has not been formally optimized.

References

Meta-Analyses & Systematic Reviews

• PMID 22137067 — Dong 2011, Am Heart J. BP meta-analysis: SBP -5.4 mmHg, DBP -2.7 mmHg.
• PMID 34967840 — Shiraseb 2022, Adv Nutr. Dose-response BP meta-analysis: SBP -6.4, greater DBP effect in females.
• PMID 27660594 — McRae 2016, J Chiropr Med. Umbrella review of arginine meta-analyses.
• PMID 19056561 — Bai 2009, Am J Clin Nutr. FMD improvement when baseline FMD low.
• PMID 30577559 — Rodrigues-Krause 2018, Nutrients. Endothelial markers in CV/metabolic disease.
• PMID 30770070 — Rhim 2019, J Sex Med. ED meta-analysis: OR 3.37 IIEF improvement.
• PMID 37908749 — Tian 2023, Front Endocrinol. L-arginine + Pycnogenol ED meta-analysis.
• PMID 33587304 — Xu 2021, Andrologia. L-arginine + PDE5i superior to PDE5i alone.
• PMID 39279185 — Barbonetti 2024, J Sex Med. Network meta-analysis: arginine+Pycnogenol exceeds MCID.
• PMID 39800868 — Makama 2025, BJOG. Preeclampsia meta-analysis: RR 0.52 prevention, RR 0.23 severe PE.
• PMID 22957482 — Zhu 2013, Hypertens Pregnancy. BP reduction in pregnant women.
• PMID 35667267 — Xu 2022, Clin Nutr. Improved neonatal outcomes in HTN/IUGR pregnancies.
• PMID 34965876 — d'Unienville 2021, J Int Soc Sports Nutr. NO precursors and endurance — arginine weak.
• PMID 39796467 — Huang 2024, Nutrients. Swimming supplements network MA.
• PMID 28537329 — Cereda 2017, J Nutr Health Aging. Disease-specific wound nutrition.
• PMID 34444657 — Arribas-López 2021, Nutrients. Arginine + glutamine pressure ulcer.
• PMID 24844870 — Vidal-Casariego 2014, Clin Nutr. Arginine-enriched formulas reduce H&N fistula.
• PMID 28429459 — Bath 2017 Cochrane. NO donors / L-arginine in acute stroke (insufficient).
• PMID 17443623 — Meher 2007 Cochrane. NO for preeclampsia prevention (insufficient 2007).
• PMID 37428872 — Pels 2023 Cochrane. NO interventions for fetal growth restriction.
• PMID 38775255 — Bolarinwa 2024 Cochrane. Antioxidants including arginine for SCD.
• PMID 38345088 — Langer 2024 Cochrane. Nutritional interventions for pressure ulcers.
• PMID 32677037 — Moore 2020 Cochrane. Diabetic foot ulcer nutrition.
• PMID 41534622 — Foncha 2026, Clin Nutr ESPEN. SCD arginine meta-analysis.

Landmark RCTs

• PMID 16391217 — Schulman 2006 VINTAGE-MI, JAMA. Post-MI excess mortality (6/70 vs 0/70, DSMB halt).
• PMID 12851125 — Stanislavov 2003, J Sex Marital Ther. First positive L-Arg + Pycnogenol ED trial.
• PMID 17703218 — Stanislavov 2008 Prelox crossover.
• PMID 21618639 — Aoki 2012, Japanese Pycnogenol + arginine IIEF study.
• PMID 40270092 — Morris 2025, Am J Hematol. Phase 2 positive for SCD VOC pain.
• PMID 35426778 — Onalo 2022 pediatric SCD hemodynamics.
• PMID 37587492 — STArT Phase 3 SCD protocol, 2023.
• PMID 39638148 — Winer 2025, Am J Clin Nutr. Citrulline in established preeclampsia multicenter.
• PMID 37789125 — Ormesher 2024, CHERRY trial citrulline in chronic HTN pregnancy.
• PMID 41248623 — Borges 2026. Arginine RCT: vasodilation yes, muscular performance no.
• PMID 41245968 — Mardokhi 2025. No anaerobic enhancement in female athletes.
• PMID 40316462 — Radovanovic 2025 ILDA COPD study.
• PMID 41364169 — Micker 2025. PAD stratified by lipid disorder.
• PMID 39683461 — Porto 2024. Null post-exercise CV/autonomic recovery.
• PMID 40389021 — Porto 2025. Null nitric oxide post-exercise.
• PMID 39985883 — Sedding 2025 CIPER trial citrulline+BH4 in PAD (Phase 2 positive).
• PMID 38745327 — Torkaman 2024. Arginine improved sexual function in women with MDD.
• PMID 38358753 — Szlosarek 2024 ATOMIC-Meso, JAMA Oncol. Pegargiminase in mesothelioma.

Mechanism & PK Studies

• PMID 40729962 — Heuser 2025, Redox Biol. RBC Arg1 dominant human arginine sink.
• PMID 39707340 — Fiordelisi 2024, Cardiovasc Diabetol. Mitochondrial biogenesis via NO-cGMP-PGC1α.
• PMID 40797410 — ADMA axis in OSA 2025.
• PMID 40429627 — ADMA disrupts tumor antigen presentation, 2025.
• PMID 41087351 — LAT1-NRF2 axis in preeclampsia, Nat Commun 2025.
• PMID 40389042 — iNOS reclassification, Pharmacol Res 2025.
• PMID 38587550 — Global arginine bioavailability in pulmonary hypertension.
• PMID 32140997 — Rashid 2020, Paediatr Drugs. Citrulline bypasses arginase.
• PMID 32568925 — Figueroa 2020, Exerc Sport Sci Rev. Citrulline vascular/muscular adaptations in older adults.
• PMID 36904267 — Park 2023, Nutrients. Citrulline generally outperforms arginine for sustained NO.
• PMID 40944179 — Figueroa 2025, Nutrients. Citrulline microvascular + muscle strength in T2DM.
• PMID 41938116 — 2026 citrulline protects against heat-stress sperm damage.

Disease-Specific

• PMID 40325816 — Vlachakis 2025. Endothelial function biomarkers review.
• PMID 38675437 — Hillsley 2024, Pharmaceuticals. Arginine/citrulline HTN trial design audit.
• PMID 36282078 — Cormio 2011, citrulline for mild ED.
• PMID 38696907 — Santo 2024, arginine-ONS chronic wounds.
• PMID 39454323 — Mehl 2025 cost-effectiveness of arginine-ONS.
• PMID 38364050 — Yang 2024 arginine-nanoenzyme diabetic wound (preclinical).
• PMID 40083304 — Dinges 2025 HFpEF/HFrEF NO metabolites.
• PMID 40795471 — Vázquez-Abuín 2025 sGC stimulation HFpEF rat.
• PMID 32640613 — Ismaeel 2020 NO system in PAD.
• PMID 38819617 — Tausendfreund 2024. Somatotroph axis in aged multimorbid.
• PMID 32236441 — Bologna 2020 arginine test HPA axis.
• PMID 34418530 — Oron 2022 combined arginine + clonidine GH stim test.
• PMID 38644716 — Vaishnavi 2025 pharmacogenomic review arginine in pregnancy.
• PMID 35309121 — Cheng 2022 citrullinemia genetics.
• PMID 35433176 — CTLN1 case report.
• PMID 40837674 — Deng 2025 CTLN1.
• PMID 39765161 — Ogawa 2025, Clin Nutr Japan. HMB + arginine + glutamine preop cardiac surgery.
• PMID 40914430 — Ogawa 2025, J Cardiol. Inflammation secondary analysis same trial.
• PMID 39564822 — Naderipour 2024 preeclampsia in high-risk.
• PMID 37258415 — Menichini 2023 preeclampsia maternal/fetal outcomes.
• PMID 39930022 — Ushida 2025 preeclampsia supplements review.
• PMID 34973154 — Long-term high-dose arginine in vasculogenic ED.

Pre-workout / Exercise Negative

• PMID 36771366 — Gonzalez 2023 NO-precursor review (weak strength evidence).

Regulatory & Safety Context

• R-Gene 10 package insert — FDA-approved IV L-arginine HCl for pituitary provocation.
• LysaKare (EMEA/H/C/004541) — EU authorized for PRRT renal protection.
• Frontiers Pharmacol 2020 — Detrimental chronic arginine on aging kidney (preclinical).
• Aging-US — Endothelial senescence long-term arginine.